Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Unlike normal B cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Rozovski, Uri, Harris, David M., Li, Ping, Liu, Zhiming, Jain, Preetesh, Ferrajoli, Alessandra, Burger, Jan, Thompson, Phillip, Jain, Nitin, Wierda, William, Keating, Michael J., Estrov, Zeev
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135679/
https://ncbi.nlm.nih.gov/pubmed/29465264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1439167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados